Patent Assignment
Reel/Frame 037394/0285
Security Interest
Recorded: 2015-12-28
Pages: 28
Assignor
MERRIMACK PHARMACEUTICALS, INC.
Executed: 2015-12-22
Assignee
U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
CORPORATE TRUST SERVICES, ONE FEDERAL STREET, 3RD FLOOR, BOSTON, MASSACHUSETTS, 02110
Covered Properties
(85)
Bispecific Binding Agents Targeting Igf-1R and ERBB3 Signalling and Uses Thereof
Application:
13/443,660 →
Publication:
US 2012/0244163
Use of Inhibitors of Egfr-Family Receptors in the Treatment of Hormone Refractory Breast Cancers
Application:
14/004,598 →
Publication:
US 2014/0134170
Use of ERBB3 Inhibitors in the Treatment of Triple Negative and Basal-Like Breast Cancers
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Application:
14/847,351 →
Publication:
US 2015/0368361
Dosage and Administration for Preventing Cardiotoxicity in Treatment with ERBB2-Targeted Immunoliposomes Comprising Anthracyclin Chemotherapeutic Agents
Dosage and Administration for Preventing Cardiotoxicity in Treatment with ERBB2-Targeted Immunoliposomes Comprising Anthracycline Chemotherapeutic Agents
Application:
14/831,199 →
Publication:
US 2016/0038416
Dosage and Administration for Preventing Cardiotoxicity in Treatment with ERBB2-Targeted Immunoliposomes Comprising Anthracycline Chemotherapeutic Agents
Monoclonal and Oligoclonal Anti-Egfr Antibodies for Use in the Treatment of Tumors Expressing Predominantly High Affinity Egfr Ligands or Tumors Expressing Predominantly Low Affinity Egfr Ligands
Application:
14/833,834 →
Publication:
US 2016/0083800
Tandem Fc Bispecific Antibodies
Application:
14/185,628 →
Publication:
US 2014/0294834
Monospecific and Bispecific Anti-Igf-1R and Anti-ERBB3 Antibodies
Monospecific and Bispecific Anti-Igf-1R and Anti-ERBB3 Antibodies
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Dosage and Administration of Monospecific and Bispecific Anti-Igr-1R and Anti-ERBB3 Antibodies
Application:
14/388,330 →
Publication:
US 2015/0231219
Compositions and Methods for Non-Invasive Imaging
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Marker Quantitation in Single Cells in Tissue Sections
Application:
14/409,808 →
Publication:
US 2015/0111217
Combination Therapy for Treating HER2-Positive Cancers
Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic Agents
Application:
14/181,583 →
Publication:
US 2014/0170075
ANTI-C-MET Tandem Fc Bispecific Antibodies
Methods and Compositions for Improving Outcomes of Liposomal Chemotherapy
Application:
14/783,619 →
Publication:
US 2016/0067182
Methods and Compositions for Improving Outcomes of Liposomal Chemotherapy
Application:
14/958,349 →
Publication:
US 2016/0184227
Biomarker Profiles for Predicting Outcomes of Cancer Therapy with ERBB3 Inhibitors and/or Chemotherapies
Dosage and Administration of Anti-IGF-1R, Anti-ErbB3 Bispecific Antibodies, Uses Thereof and Methods of Treatment Therewith
Application:
62/103,963 →
Dosage and Administration of Anti-Egfr Therapeutics
Combination Therapies for Treating HER2-Positive Cancers That Are Resistant to HER2-Targeted Therapies
Application:
14/819,317 →
Publication:
US 2016/0045596
Predicting Tumor Responses to Antibodies Against Hepatocyte Growth Factor (Hgf) and/or Its Cognate Receptor, C-Met
Application:
62/217,441 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And
Application:
62/265,409 →
Treatment of Breast Cancer with Liposomal Irinotecan
Application:
14/964,571 →
Publication:
US 2016/0346272
Methods for Improving the Pharmacokinetics and Therapeutic Index of Sustained Release Drug Therapies
Application:
62/147,389 →
Combination Treatments with Seribantumab
Application:
62/149,271 →
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monoclonal Anti-Egfr Antibodies
Application:
62/244,991 →
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monocolonal Anti-Egfr Antibodies
Application:
62/152,707 →
Combination Cancer Therapies
Application:
62/168,553 →
Combination of Cancer Therapies
Application:
62/245,825 →
Biomarkers for Predicting Outcomes of Cancer Therapy with ErbB3 Inhibitors and/or Chemotherapies
Application:
62/171,062 →
DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES THEREOF AND METHODS OF TREATMENT THEREWITH
Application:
62/182,889 →
DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES THEREOF AND METHODS OF TREATMENT THEREWITH
Application:
62/245,743 →
Combination Therapy for Cancer Treatment
Application:
62/207,709 →
Combination Therapy for Cancer Treatment
Application:
62/207,760 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/216,736 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/208,209 →
Combination Therapies for Treatment of Heregulin Positive Cancers
Application:
62/210,838 →
Liposomes with Improved Stability
Application:
62/242,835 →
Irinotecan liposomes with improved stability
Application:
62/244,061 →
Liposomes with Improved Stability
Application:
62/244,082 →
Liposomes with Improved Stability
Application:
62/242,873 →
Methods of Treating Cancer by Administering a Bispecific Antibody Antagonist of Igf-Ir and ERBB3 and a Combination of Anti-Egfr Antibodies
Application:
62/244,981 →
Methods of Treating Cancer by Administering a Mek Inhibitor and a Combination of Anti-Egfr Antibodies
Application:
62/244,941 →
Liposomes Useful for Drug Delivery to the Brain
Application:
14/151,632 →
Publication:
US 2014/0127136
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
14/964,239 →
Publication:
US 2016/0081928
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
14/879,358 →
Publication:
US 2016/0030342
Liposomes Useful for Drug Delivery
DISULFIDE-STABILIZED Fab FRAGMENTS
Application:
62/263,368 →
Compositions and Methods for Delivering Nucleic Acid to a Cell
Application:
13/967,664 →
Publication:
US 2014/0065204
Methods, Systems and Products for Predicting Response of Tumor Cells to a Therapeutic Agent and Treating a Patient According to the Predicted Response
Application:
14/148,379 →
Publication:
US 2014/0127238
Antibodies Against the Ectodomain of ERBB3 and Uses Thereof
Antibodies Against ERBB3 and Uses Thereof
Antibodies Against the Ectodomain of ERBB3 and Uses Thereof
Antibodies Against ERBB3 and Uses Thereof
Methods and Systems for Predicting Response of Cells to a Therapeutic Agent
Use of ERBB3 Inhibitors in the Treatment of Triple Negative and Basal-Like Breast Cancers
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Methods of Treatment of Tumors Expressing Predominantly High Affinity Egfr Ligands or Tumors Expressing Predominantly Low Affinity Egfr Ligands with Monoclonal and Oglioclonal Anti-Egfr Antibodies
Bispecific Anti-Igf-1R and Anti-ERBB3 Antibodies
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery to the Brain
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Bispecific Binding Agents for Modulating Biological Activity
Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic Agents
PCT:
PCT/US2013/075513 ↗
Liposomes Useful for Non-Invasive Imaging and Drug Delivery
PCT:
PCT/US2014/062007 ↗
Dosage and Administration of Anti-Igf-1R, Anti-ERBB3 Bispecific Antibodies, Uses Thereof and Methods of Treatment Therewith
PCT:
PCT/US2015/016672 ↗
Dosage and Administration Anti-Egfr Therapeutics
PCT:
PCT/US2015/030870 ↗
Combination Therapies for Treating HER2-Positive Cancers That Are Resistant to HER2-Targeted Therapies
PCT:
PCT/US2015/043867 ↗
Predicting Tumor Responses to Antibodies Against Hepatocyte Growth Factor (Hgf) and/or Its Cognate Receptor, C-Met
PCT:
PCT/US2015/053561 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 19, 2012
From: SCHOEBERL, BIRGIT; NIELSEN, ULRIK; KUDLA, ARTHUR J.; LUGOVSKOY, ALEXEY ALEXANDROVICH
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 028402/0530 →
Assignment of Assignor's Interest
Jun 19, 2012
From: MURUGANANDAM, ARUMUGAM; BUCKLER, DAVID
To: DYAX CORP.
Reel/Frame 028402/0568 →
Assignment of Assignor's Interest
Sep 5, 2013
From: REYNOLDS, JOSEPH G.; OLIVIER, KENNETH J., JR.; HENDRIKS, BART S.; WICKHAM, THOMAS
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 031144/0967 →
Assignment of Assignor's Interest
Mar 11, 2014
From: HARMS, BRIAN; KOHLI, NEERAJ; LUGOVSKOY, ALEXEY; SU, STEPHEN
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 032403/0666 →
Assignment of Assignor's Interest
Jun 18, 2014
From: BAUM, JASON; JOHNSON, BRYAN; LUGOVSKOY, ALEXEY ALEXANDROVICH; XU, LIHUI
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033125/0775 →
Assignment of Assignor's Interest
Sep 29, 2014
From: LUGOVSKOY, ALEXEY ALEXANDROVICH; BAUM, JASON; ADAMS, SHARLENE
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033836/0823 →
Assignment of Assignor's Interest
Oct 21, 2014
From: MOYO, VICTOR; GARCIA, GABRIELA
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033988/0911 →
Assignment of Assignor's Interest
Oct 27, 2014
From: FELDHAUS, MICHAEL; KRAULAND, ERIC
To: ADIMAB, LLC
Reel/Frame 034043/0635 →
Assignment of Assignor's Interest
Oct 27, 2014
From: ADIMAB, LLC
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034043/0657 →
Assignment of Assignor's Interest
Oct 27, 2014
From: BUKHALID, RAGHIDA; KING, ANNE; KOHLI, NEERAJ; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034043/0615 →
Assignment of Assignor's Interest
Apr 21, 2015
From: BAYEVER, ELIEL; DHINDSA, NAVREET; FITZGERALD, JONATHAN BASIL; LAIVINS, PETER
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 035460/0337 →
Assignment of Assignor's Interest
Aug 25, 2015
From: BUKHALID, RAGHIDA; NIELSEN, ULRIK; WERNER, SHANNON; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 036408/0577 →
Assignment of Assignor's Interest
Sep 29, 2015
From: BAUM, JASON; JOHNSON, BRYAN; LUGOVSKOY, ALEXEY ALEXANDROVICH; XU, LIHUI
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 036685/0853 →
Assignment of Assignor's Interest
Oct 1, 2015
From: HARMS, BRIAN; KOHLI, NEERAJ; LUGOVSKOY, ALEXEY; SU, STEPHEN
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 036705/0343 →
Assignment of Assignor's Interest
Nov 11, 2015
From: DYAX CORP.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037014/0259 →
Assignment of Assignor's Interest
Nov 20, 2015
From: BUKHALID, RAGHIDA; KING, ANNE; KOHLI, NEERAJ; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037103/0947 →
Assignment of Assignor's Interest
Nov 20, 2015
From: BUKHALID, RAGHIDA; KING, ANNE; KOHLI, NEERAJ
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037099/0896 →
Assignment of Assignor's Interest
Nov 20, 2015
From: FELDHAUS, MICHAEL; KRAULAND, ERIC
To: ADIMAB, LLC
Reel/Frame 037099/0902 →
Assignment of Assignor's Interest
Nov 20, 2015
From: ADIMAB, LLC
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037099/0906 →
Assignment of Assignor's Interest
Nov 20, 2015
From: NIELSEN, ULRIK
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037099/0909 →
Assignment of Assignor's Interest
Nov 20, 2015
From: FELDHAUS, MICHAEL; KRAULAND, ERIC
To: ADIMAB, LLC
Reel/Frame 037103/0892 →
Assignment of Assignor's Interest
Nov 20, 2015
From: FELDHAUS, MICHAEL; KRAULAND, ERIC
To: ADIMAB, LLC
Reel/Frame 037103/0900 →
Assignment of Assignor's Interest
Nov 20, 2015
From: FELDHAUS, MICHAEL; KRAULAND, ERIC
To: ADIMAB, LLC
Reel/Frame 037103/0908 →
Assignment of Assignor's Interest
Nov 20, 2015
From: BUKHALID, RAGHIDA; KING, ANNE; KOHLI, NEERAJ; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037103/0925 →
Assignment of Assignor's Interest
Nov 20, 2015
From: BUKHALID, RAGHIDA; KING, ANNE; KOHLI, NEERAJ; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037103/0938 →